In one paragraphArticle in The Journal of experimental medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
23 authors.
Kyle RhodehouseDepartment of Medicine, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.ORCID 0000-0002-4668-3172 Meghana RaviDepartment of Medicine, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.ORCID 0009-0003-0230-9642 Ciara ArmstrongDepartment of Medicine, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.ORCID 0009-0002-2674-9493 Milica MoskovljevicDepartment of Medicine, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.ORCID 0000-0003-0436-6854 Hannah P MooreDepartment of Medicine, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.ORCID 0000-0001-7566-4213 Courtney SchillDepartment of Medicine, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.ORCID 0000-0002-2841-7612 Emily J FrayDepartment of Medicine, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.ORCID 0000-0002-5850-6237 Mithra R KumarDepartment of Medicine, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.ORCID 0000-0001-8361-7935 Miranda R StaussWisconsin National Primate Research Center, University of Wisconsin-Madison , Madison, WI, USA.ORCID 0000-0003-3734-8329 Roger W WisemanWisconsin National Primate Research Center, University of Wisconsin-Madison , Madison, WI, USA.ORCID 0000-0002-7682-7085 David H O'ConnorWisconsin National Primate Research Center, University of Wisconsin-Madison , Madison, WI, USA.ORCID 0000-0003-2139-470X Christine M FennesseyAIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research , Frederick, MD, USA.ORCID 0000-0002-8736-8523 Brandon F KeeleAIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research , Frederick, MD, USA.ORCID 0000-0002-2381-1151 Jeffrey D LifsonAIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research , Frederick, MD, USA.ORCID 0000-0002-9494-0268 Janet D SilicianoDepartment of Medicine, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.ORCID 0000-0001-6712-3775 Robert F SilicianoDepartment of Medicine, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.ORCID 0000-0002-1764-1993 Funding
WORK ORDER 126643 B539 EXPAND IC SUITE75N91019D00024 · NIAID · LEIDOS BIOMEDICAL RESEARCH, INC. · PI BRISCOE, LYNN · 2019 to 2025
$3932.6MWNPRC Supplemental Request for Nonhuman Primate Enclosures to Equip HIV/AIDS-Related Research FacilitiesP51OD011106 · OD · UNIVERSITY OF WISCONSIN-MADISON · PI Dorota A. Grejner-Brzezinska · 2012 to 2026
$150.7MTulane NPRC SPF Sheltered Outdoor Enclosure ExpansionP51OD011104 · OD · TULANE UNIVERSITY OF LOUISIANA · PI L Lee HAMM · 2012 to 2026
$142.4MBEAT-HIV: Delaney Collaboratory to Cure HIV-1 Infection by Combination ImmunotherapyUM1AI164570 · NIAID · WISTAR INSTITUTE · PI Luis J Montaner, James L. Riley · 2021 to 2026
$34.7MDelaney AIDS Research Enterprise to Cure HIVUM1AI164560 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI STEVEN Grant DEEKS, Sharon Ruth Lewin · 2021 to 2026
$32.0MReversing Immune Dysfunction for HIV-1 EradicationUM1AI164561 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI SUMIT K CHANDA, Paula M Cannon · 2021 to 2026
$30.0MI4C 2.0: Immunotherapy for CureUM1AI164556 · NIAID · BETH ISRAEL DEACONESS MEDICAL CENTER · PI Dan H. Barouch, John W Mellors · 2021 to 2026
$28.0MBIOCHEMISTRY, CELLULAR AND MOLECULAR BIOLOGY PROGRAMT32GM007445 · NIGMS · JOHNS HOPKINS UNIVERSITY · PI GREEN, RACHEL · 1985 to 2021
$24.1MUnderstanding reservoir dynamics through analysis of viral decay processesP01AI169615 · NIAID · JOHNS HOPKINS UNIVERSITY · PI ALAN S PERELSON · 2022 to 2026
$9.5MBiochemistry, Cellular and Molecular Biology Program: JHU BioGREAT (Biomedical Graduate REsiliency & Adaptability Training)T32GM144272 · NIGMS · JOHNS HOPKINS UNIVERSITY · PI Takanari Inoue · 2022 to 2026
$5.4MModeling Viral and T Lymphocyte DynamicsR01OD011095 · OD · TRIAD NATIONAL SECURITY, LLC · PI PERELSON, ALAN S · 2012 to 2024
$5.0MNon-human primate MHC and KIR Allele Discovery and Typing Technology Development 75N93021C00006 · NIAID · UNIVERSITY OF WISCONSIN-MADISON · PI O'CONNER, PHD, DAVID · 2021 to 2025
$4.9MHoward Hughes Medical InstituteNational Institute of Allergy and Infectious Diseases UM1AI164561NCI NIH HHS 75N91019D00024NCI NIH HHS P01 AI169615NCI NIH HHS R01OD011095NCI NIH HHS UM1AI164561NIAID NIH HHS 75N93021C00006NIAID NIH HHS P01 AI169615NIAID NIH HHS R01 AI152765NIAID NIH HHS UM1 AI164556NIAID NIH HHS UM1 AI164560NIAID NIH HHS UM1 AI164561NIAID NIH HHS UM1 AI164570NIGMS NIH HHS T32 GM007445NIGMS NIH HHS T32 GM144272NIH HHS P01AI169615NIH HHS P51 OD011104NIH HHS P51 OD011106NIH HHS R01AI152765NIH HHS R01 OD011095NIH HHS R01OD011095NIH HHS T32GM007445NIH HHS T32GM144272NIH HHS UM1AI164556NIH HHS UM1AI164560NIH HHS UM1AI164561NIH HHS UM1AI164570Tulane National Biomedical Research Center OD011104Wisconsin National Primate Research Center P51OD011106
6 · The paper itselfAbstract
Insights into HIV-1 pathogenesis have come from studies of viral dynamics. However, there is little information on viral dynamics in lentiviral infections in which viral replication is naturally controlled in a subset of infected individuals. We evaluated the decay of simian immunodeficiency virus (SIV) RNA and cell-associated SIV genomes in a nonhuman primate (NHP) model in which replication of an engineered SIV variant is naturally controlled by cellular immune responses in most infected animals. This variant lacks a trafficking motif in the gp41 cytoplasmic tail. A trajectory of control was evident by 21 days after infection. In animals with natural control, we observed similar biphasic decay of intact proviruses in blood and lymph nodes, at rates close to those in animals that failed to control the virus and were put on antiretroviral therapy (ART). Both natural control and ART effectively blocked viral evolution, but not persistence. Thus, in this NHP model, natural control can be nearly as effective as ART in controlling viral replication.
Indexed as
Simian Acquired Immunodeficiency SyndromeSimian Immunodeficiency VirusViral EnvelopeAnimalsAnti-Retroviral AgentsHumansMacaca mulattaRNA, ViralVirus ReplicationAnti-Retroviral AgentsRNA, Viral
Identifiers
PMID41348110
PMCPMC12679998
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390